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Acute Presentation of Structural Valve Degeneration in a
Transcatheter Heart Valve (Sapien XT) at 7.5 Years;
Successful Redo TAVR With a Sapien 3 Ultra
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William Moody, MBBS, MRCP, PhD, and Jonathan N. Townend, BSc, MBChB, FRCP, MD
Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, United KingdomABSTRACT
Little is known about the presentation of structural valve degeneration
complicating transcatheter heart valves (THVs). We report a case of
acute heart failure, secondary to leaflet prolapse, in a previously well
77-year-old man, 7.5 years after successful transcatheter aortic valve
replacement with a 26-mm balloon-expandable Sapien XT (Edwards
Lifesciences, Irvine, CA) THV. This case highlights that structural valve
degeneration complicating THVs might lead to acute presentation with
little warning from previous echocardiograms. Calcification might be
absent on imaging. Redo transcatheter aortic valve replacement is
feasible and appears safe. Post deployment optimization with a highly
noncompliant balloon might improve full expansion of the newly
implanted THV and improve valve performance.Received for publication September 28, 2020. Accepted November 2, 2020.
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On en sait peu sur les manifestations associees à une degenerescence
structurelle d’une prothèse valvulaire après implantation par catheter.
Nous presentons un cas d’insuffisance cardiaque aiguë secondaire à
un prolapsus valvulaire chez un homme de 77 ans qui jusque-là allait
bien, survenu 7,5 ans après l’implantation par catheter d’une valve
cardiaque de 26 mm Sapien XT (Edwards Lifesciences, Irvine, CA). Ce
cas montre qu’une degenerescence structurelle de la prothèse valvu-
laire peut entraîner une manifestation aiguë sans que des signes
precurseurs soient detectes à l’echocardiographie. Il peut arriver que
les examens d’imagerie ne revèlent pas de calcification. Il est possible
d’implanter une autre valve aortique par catheter pour remplacer la
prothèse defaillante, une intervention qui semble sûre. Une optimisa-
tion à l’aide d’un ballonnet non compliant pourrait faciliter l’expansion
complète de la nouvelle valve cardiaque implantee par catheter et en
ameliorer le fonctionnement.Until recently transcatheter aortic valve replacement (TAVR) history of progressive exertional breathlessness (New York
has been used principally in elderly, high-risk populations
with limited life expectancy. Failure of transcatheter heart
valves (THVs) due to structural valve degeneration (SVD),
requiring urgent reintervention, is an uncommon occurrence.
There are relatively few data on the timing, mode of presen-
tation, valvular imaging characteristics, and outcomes of redo
TAVR in this situation. We describe the first case of redo
TAVR for SVD at our institution after more than 1000
TAVR cases, 7.5 years after successful TAVR at our centre.Case
In March 2020, during the COVID-19 pandemic, a 77-
year-old man was admitted emergently with a 5-monthHeart Association [NYHA] classification III) and orthopnea.
Before this he had been well and unlimited in his daily activity
(NYHA class I). He denied fevers or sweats. Examination
revealed evidence of heart failure with raised jugular venous
pressure, mild chest crepitations, and ankle swelling. Auscul-
tation revealed an ejection systolic murmur at the aortic area
and an early diastolic murmur of aortic regurgitation. His C-
reactive protein was elevated at 37 mg/L (reference < 5 mg/
L), hemoglobin was low at 11.7 g/dL, and estimated
glomerular filtration rate reduced at 43 mL/min. Two reverse
transcriptase polymerase chain reaction assays on nasopha-
ryngeal swabs were negative for SARS-CoV-2 virus.
In September 2012 the patient underwent transfemoral
TAVR with a 26-mm Sapien XT valve (Edwards Lifesciences,
Irvine, CA) for severe aortic stenosis (Fig. 1A; see Video 1
; view video online). At the time, the patient was 69
years of age and deemed high risk for open heart surgery
because of previous bypass surgery in 2003, with 3 patent
grafts, and acute presentation with kidney failure. After TAVR
transthoracic echocardiogram (TTE) showed a peak velocity
(VMax) of 1.6 m/s, mean gradient of 9 mm Hg, and aortic
valve area (AVA) 2.02 cm2 with trivial paravalvularis is an open access article under the CC BY license (http://creativecommons.
Novel Teaching Points
 This case highlights that SVD complicating THVs
might lead to acute presentation with heart failure with
little warning from previous echocardiograms.
 Unlike degeneration in native aortic valves, calcification
might be absent.
 Redo TAVR is feasible and appears to have a safety
profile similar to first-time TAVR.
 Post deployment optimization with a highly non-
compliant balloon might serve to facilitate full expan-
sion of the newly implanted THV and improve valve
performance.
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Volume 3 2021regurgitation and no transvalvular regurgitation. His left
ventricular ejection fraction (LVEF) was 50%-55%. His other
history included paroxysmal atrial fibrillation, mild ischemic
stroke, and pacemaker implanted for symptomatic
bradycardia.
In July 2019 the patient was investigated for atypical chest
pain. TTE at that time showed an LVEF of 55% and a well
functioning THV prosthesis. His VMax was 2.6 m/s, mean
gradient 17 mm Hg, and AVA 1.5 cm2. There was noFigure 1. (A) Aortogram after deployment of 26-mm Sapien XT (Edwards Life
stenosis showed absence of aortic regurgitation. (B) Transoesophageal ech
opening of the 26-mm Sapien XT valve but evidence of modest leaflet thicken
2020) in long axis view showed prolapse of a transcatheter heart valve cu
eccentric, severe aortic regurgitation (3D vena contracta area 0.31 cm2) dutransvalvular regurgitation and trivial paravalvular
regurgitation. Computed tomography (CT) coronary angi-
ography showed 3 patent grafts.
The patient’s current presentation was believed to be
consistent with a diagnosis of either infective endocarditis or
SVD causing leaflet prolapse. Urgent TTE showed severe aortic
regurgitation but could not discern if this was trans- or para-
valvular. His VMaxwas 2.9m/s,mean gradient 16mmHg, and
left ventricular function was severely impaired (LVEF 30%).
There was mild mitral regurgitation. Urgent transoesophageal
echocardiogram (TEE) showed degenerative changes of the
THV with leaflet thickening but good opening and no vege-
tations (Fig. 1B; see Video 2 ; view video online). There
was a severe, eccentric, jet of aortic regurgitation (3D vena
contracta area 0.31 cm2) due to prolapse of a THV cusp,
(Fig. 1C andD; see Video 3 andVideo 4 ; view videos
online). A gated cardiac CT image showed no calcification of
the THV leaflets, pannus formation, leaflet thrombus, or ab-
scess (Fig. 2A; see Video 5 ; view video online).
Heart failure was treated with intravenous diuretics,
angiotensin-converting enzyme inhibitors and b-blockers.
Over 2 weeks, multiple blood cultures showed no bacterial
growth. His C-reactive protein normalized without antibiotic
therapy and the patient’s breathlessness improved. SVD was
now believed to be the most likely diagnosis. The patient wassciences Corp, Irvine, CA) valve in September 2012 for severe aortic
ocardiogram (TEE) (March 2020), in the short axis view, showed good
ing, secondary to structural valve degeneration (arrow). (C) TEE (March
sp (arrow). (D) TEE (March 2020) in long axis view showed a jet of
e to cusp prolapse.
Figure 2. (A) Gated computed tomography aortogram (March 2020) showed complete absence of leaflet calcification of the Sapien XT (Edwards
Lifesciences Corp, Irvine, CA) prosthesis (short axis left image, midframe level). (B) In April 2020 redo transcatheter aortic valve replacement was
undertaken with a 26 mm Sapien 3 Ultra valve (Edwards Lifesciences Corp) via percutaneous transfemoral access. The top of the Sapien 3 Ultra
was aligned with the top of the Sapien XT transcatheter heart valve. (C) Post dilatation was undertaken with a 26-mm Atlas Gold PTA Dilatation
Catheter (Bard Peripheral Vascular, Inc, Tempe, AZ) balloon to 12 atm (nominal pressure 4 atm) to optimize expansion of the Sapien 3 and
improve valve performance. (D) Root aortography after deployment and after optimization of the 26-mm Sapien 3 Ultra valve showed no aortic
regurgitation.
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Clinical, Imaging Characteristics and Managementdeemed high risk for open heart surgery and percutaneous
transfemoral valve in valve TAVR was considered the optimal
treatment. The pacemaker was upgraded to a CRT-P (Boston
Scientific, Marlborough, MA) and in April 2020, the patient
underwent transfemoral TAVR with a 26-mm Sapien 3 Ultra
(Edwards Lifesciences Corp) valve. The native coronary
arteries took origin well above the Sapien XT prosthesis and
there was therefore deemed to be no risk of native coronary
artery occlusion or impaired coronary access. The Sapien 3
Ultra was positioned to align the top of the frame with the top
of the Sapien XT THV (Fig. 2B; see Video 6 ; view video
online). Post dilatation was performed with a 26-mm Atlas
Gold balloon (Bard Peripheral Vascular Inc, Tempe, AZ) to
12 atm (Fig. 2C). There was no aortic regurgitation on
aortography (Fig. 2D; see Video 7 ; view video online).
Post procedure TTE showed good function of the
prosthesis with a VMax of 1.8 m/s, maximum pressure
gradient of 13 mm Hg, mean pressure gradient of 6.7 mm
Hg, and AVA 2.0 cm2 with no transvalvular or paravalvular
regurgitation.There were no complications and the patient was dis-
charged the next day with Apixaban 5 mg oral anticoagulation
twice daily and heart failure medications. At the 8-week re-
view the patient reported steadily improving exercise capacity
(NYHA class II) and freedom from orthopnea and ankle
swelling. At 21 weeks the patient had improved further
(NYHA class I) and had undergone no admissions. An
echocardiogram showed improved left ventricular function
(ejection fraction 43%), stable valve parameters, and no trans-
or paravalvular regurgitation.
Discussion
Although the durability of THVs has been shown to be
good in high-risk cohorts, SVD can be expected to occur
during extended follow-up, resulting in THV failure that
might require reintervention.1-3 SVD might present as
stenosis or regurgitation.4 In the largest observational study of
redo TAVR, among 63,876 TAVR procedures, 212 patients
underwent redo TAVR (0.22%).5 The median time to redo
TAVR was 5 years. The indication for redo TAVR beyond 1
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Volume 3 2021year was regurgitation or combined stenosis/regurgitation in
62.3%. The low rate of redo TAVR likely reflects the good
durability of THVs and limited life expectancy of the cohort
studied. In the 5-year follow-up of the randomized Placement
of Aortic Transcatheter Valves (PARTNER) 2 study, in which
TAVR was compared with open heart surgery in intermediate-
risk patients (Society of Thoracic Surgeons 4%-8%), aortic
valve interventions were more frequently observed in the
TAVR group (3.2% vs 0.8%).6 Of the 21 reinterventions
after TAVR, 10 were for progressive aortic stenosis whereas 11
were for aortic regurgitation, and 17 were treated with redo
TAVR (1.7%).
In our case, THV failure appears to have occurred
relatively insidiously. Although the TTE in July 2019 showed
increased transvalvular velocities, compared with the
immediate post-deployment TTE in 2012, there was no
transvalvular regurgitation. The TEE of March 2020 showed
modest leaflet thickening with good opening but severe aortic
regurgitation due to leaflet prolapse. The CT aortogram
showed absence of leaflet calcification. We postulate that a
leaflet tear occurred as a result of SVD, resulting in leaflet
prolapse with resultant severe aortic regurgitation.
Redo TAVR would appear to have a safety profile similar
to first-time TAVR. There were no mortalities in patients who
underwent redo TAVR in the 5-year PARTNER 2 follow-up
study or the registry of 212 patients who underwent redo
TAVR.5,6 However, a recently highlighted problem after redo
TAVR is impaired access to the native coronary arteries due to
displaced leaflets of the first THV. A recent study in 137
patients showed coronary angiography to be unfeasible in
31% after redo TAVR.7 This difficulty can be overcome by
deeper placement of the initial THV into the left ventricular
outflow tract but might be associated with more pacemaker
requirement. In the study of redo TAVR in 212 patients, high
residual gradients (mean > 20 mm Hg) were observed in
14.3%.5 In the present case, post dilatation was performed
with a highly noncompliant balloon to optimize expansion of
the THV with the aim of improving valvular performance.
The peak and mean gradients observed after balloon
optimization in our case were similar to the parameters
observed after the first TAVR in 2012. This observation
would support the notion that final dilatation with a highly
noncompliant balloon might be reasonable, in an attempt tooptimize expansion of the newly implanted THV and thus
improve valve performance.Funding Sources
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